News >

Efforts Expand for Targeting Rare Alterations in NSCLC

Kristi Rosa
Published: Wednesday, Feb 19, 2020

Karen L. Reckamp, MD, medical director, Clinical Research Operations, City of Hope Comprehensive Cancer Center

Karen L. Reckamp, MD

The list of less-common targetable mutations that are under investigation in non–small cell lung cancer (NSCLC) continues to expand, according to Karen Reckamp, MD, MS, and several novel therapies developed for these alterations have either already received regulatory approval or are showing promise in clinical trials.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication